BCDA · BioCardia, Inc. · Earnings Call Transcripts & Audio
$1.09
-0.02 (-1.80%)
At close · Sep 9
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about our ability to continue as a going concern beyond one year from the date these financial statements are issued. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Our ability to continue as a going concern and to continue further development of our therapeutic candidates beyond January 2027 will require us to raise additional capital, possibly through licensing certain product rights. We plan to raise additional capital, potentially including non-dilutive collaboration and licensing arrangements, debt or equity financing, or a combination from these sources to finance our future operations. While management believes this plan to raise additional funds will alleviate the conditions that raise substantial doubt, these plans are not entirely within their control and cannot be assessed as being probable of occurring.”View the 10-Q filed Aug 12, 2026
Market Cap
$16.43M
Shares
15.14M
BioCardia, Inc. Earnings Call Transcripts
Quarterly earnings calls for BioCardia, Inc. (BCDA), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▼74.2%
$212,000
−$3.06M
'22 Q3
22-11-09
▲34.2%
$106,000
−$3.03M
'22 Q4
23-03-29
▲6.7%
$64,000
−$3.50M
'23 Q1
23-05-10
▼95.6%
$43,000
−$3.42M
'23 Q2
23-08-09
▲68.4%
$357,000
−$2.57M
'23 Q3
23-11-08
▼87.7%
$13,000
−$2.07M
'23 Q4
24-03-27
▼14.1%
$55,000
−$2.27M
'24 Q1
24-05-14
▼93%
$3,000
−$1.65M
'24 Q2
24-08-13
▼100%
$
−$1.74M
'24 Q3
24-11-13
▼100%
$
−$2.30M
'24 Q4
25-03-26
▼100%
$
−$2.71M
'25 Q1
25-05-14
▼100%
$
−$2.05M
'25 Q2
25-08-11
·
$
−$1.48M
'25 Q3
25-11-12
LATEST
·
$
−$1.98M
'25 Q4
26-03-24
Earnings call
FY26 · Q2
2026-08-12
BioCardia, Inc. (BCDA) Q2 2026 Earnings Call Transcript
Confident tone
Japan PMDA regulatory progress for CardiAMP
FDA confirmatory trial pathway for CardiAMP-HF2
Helix Transcendocardial Delivery Catheter de novo pathway
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-15
BioCardia, Inc. (BCDA) Q1 2026 Earnings Call Transcript
Confident tone
Japan PMDA regulatory pathway
Market opportunity and reimbursement
Helix Transendocardial Delivery System
Diluted EPS
$-0.21
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-24
BioCardia, Inc. (BCDA) Q4 2025 Earnings Call Transcript
Confident tone
Partnership and business development
CardiAMP HF Phase III results
Regulatory pathway and FDA/PMDA engagement
Revenue
$*
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-12
BioCardia, Inc. (BCDA) Q3 2025 Earnings Call Transcript
Positive tone
Japan PMDA regulatory progress
FDA regulatory engagement
Helix transendocardial delivery system
Revenue
$
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-11
BioCardia, Inc. (BCDA) Q2 2025 Earnings Call Transcript
Positive tone
Japan PMDA Submission and Partnership Opportunity
CardiAMP Heart Failure Trial Results and Regulatory Pathway
Business Development and Partnering
Revenue
$
▼ 100% YoY Diluted EPS
$-0.40
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-14
BioCardia, Inc. (BCDA) Q1 2025 Earnings Call Transcript
Positive tone
Tariffs and Most Favored Nation Pricing
Business Development and Partnerships
Morph DNA Steerable Introducer Platform
Revenue
$
▼ 100% YoY Diluted EPS
$-0.59
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-26
BioCardia, Inc. (BCDA) Q4 2024 Earnings Call
Revenue
$*
▼ 100% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-13
BioCardia, Inc. (BCDA) Q3 2024 Earnings Call Transcript
Confident tone
Japan Regulatory Pathway (PMDA)
CardiAMP Heart Failure I Trial Readout
CardiAMP Heart Failure II Trial Enrollment
Revenue
$
▼ 100% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-13
BioCardia, Inc. (BCDA) Q2 2024 Earnings Call Transcript
Positive tone
CardiALLO Allogeneic Cell Therapy
CardiAMP Heart Failure I Trial
Business Development and Partnerships
Revenue
$3,000
▼ 93% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-14
BioCardia, Inc. (BCDA) Q1 2024 Earnings Call Transcript
Confident tone
Japan PMDA Regulatory Pathway
CardiAMP Heart Failure Trial Results
Japanese Commercialization Strategy
Revenue
$55,000
▼ 14.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-27
BioCardia, Inc. (BCDA) Q4 2023 Earnings Call Transcript
Positive tone
Unmet Need in Heart Failure
Clinical Trial Execution and Enrollment
CardiAMP Heart Failure Trial (BCDA-01) Results
Revenue
$13,000*
▼ 87.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-08
BioCardia, Inc. (BCDA) Q3 2023 Earnings Call Transcript
Revenue
$357,000
▲ 68.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-09
BioCardia, Inc. (BCDA) Q2 2023 Earnings Call Transcript
Revenue
$43,000
▼ 95.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-10
BioCardia, Inc. (BCDA) Q1 2023 Earnings Call Transcript
Revenue
$64,000
▲ 6.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-29
BioCardia, Inc. (BCDA) Q4 2022 Earnings Call Transcript
Revenue
$106,000*
▲ 34.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-09
BioCardia, Inc. (BCDA) Q3 2022 Earnings Call Transcript
Revenue
$212,000
▼ 74.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-10
BioCardia, Inc. (BCDA) Q2 2022 Earnings Call Transcript
Revenue
$974,000
▲ 1311.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-11
BioCardia, Inc. (BCDA) Q1 2022 Earnings Call Transcript
Revenue
$60,000
▲ 30.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-29
BioCardia, Inc. (BCDA) Q4 2021 Earnings Call Transcript
Revenue
$79,000*
▲ 71.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q1
2021-05-13
BioCardia, Inc. (BCDA) Q1 2021 Earnings Call
Revenue
$46,000
▲ 21.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-03-30
BioCardia, Inc. (BCDA) Q4 2020 Earnings Call
Revenue
$46,000*
▼ 78.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q2
2020-08-13
BioCardia, Inc. (BCDA) Q2 2020 Earnings Call
Revenue
$27,000
▼ 68.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Showing 1–22 of 22 earnings calls
Key facts
CIK
925741
CUSIP
09060U606
13F (30d)
13 filings
13 filers
Visit website
Investor relations